Xbiome Signs $139 Million China Deal for Probiotic Diabetic Foot Ulcer Therapy
publication date: Jan 28, 2022
Xbiome, a Shenzhen AI-based microbiome drug development company, in-licensed China rights to an inflammatory disease therapy developed by Aurealis, a Swiss synthetic biology company, in a deal worth up to $139 million. Xbiome will develop AUP-16 in Greater China for Diabetic Foot Ulcer (DFU) and other chronic wounds. AUP-16 is a genetically engineered Lactococcus lactis, a non-pathogenic, probiotic bacteria. Last month, Xbiome completed a B+ funding of nearly $100 million. It has been approved to begin US trials of its lead program, an oral microbiome therapy for graft-versus-host disease. More details....
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.